Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Background - Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a mod...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
9 August 2022
|
| In: |
Annals of oncology
Year: 2022, Jahrgang: 33, Heft: 11, Pages: 1149-1158 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2022.07.1940 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2022.07.1940 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753422037917 
|
| Verfasserangaben: | S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J.-U. Blohmer, J. Furlanetto, D.-M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P.A. Fasching, V. Nekljudova, C. Denkert & M. Untch, on behalf of GBG and AGO-B |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1831514176 | ||
| 003 | DE-627 | ||
| 005 | 20240326080406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230119s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2022.07.1940 |2 doi | |
| 035 | |a (DE-627)1831514176 | ||
| 035 | |a (DE-599)KXP1831514176 | ||
| 035 | |a (OCoLC)1389536167 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response |c S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J.-U. Blohmer, J. Furlanetto, D.-M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P.A. Fasching, V. Nekljudova, C. Denkert & M. Untch, on behalf of GBG and AGO-B |
| 264 | 1 | |c 9 August 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.01.2023 | ||
| 520 | |a Background - Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a moderate increase in pathological complete response (pCR) rate by an absolute 9% (P = 0.287). - Patients and methods - Patients with cT1b-cT4a-d triple-negative breast cancer (TNBC) received durvalumab 1.5 g or placebo every 4 weeks added to nab-paclitaxel 125 mg/m2 weekly for 12 weeks, followed by durvalumab/placebo every 4 weeks plus epirubicin/cyclophosphamide every 2 weeks followed by surgery. Durvalumab was not continued after surgery. The primary objective was pCR. Secondary endpoints included invasive disease-free survival (iDFS), distant disease-free survival (DDFS) and overall survival (OS). - Results - A total of 174 patients were randomised between June 2016 and October 2017. After a median follow-up of 43.7 months, 34 events had occurred. Despite a non-significant increase in the pCR rate, significant differences were observed for 3-year iDFS, DDFS and OS: iDFS was 85.6% with durvalumab versus 77.2% with placebo [hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.24-0.97, stratified log-rank P = 0.036]; DDFS 91.7% versus 78.4% (HR 0.31, 95% CI 0.13-0.74, P = 0.005); OS 95.2% versus 83.5% (HR 0.24, 95% CI 0.08-0.72, P = 0.006). pCR patients had 3-year iDFS of 95.5% with durvalumab and 86.1% without (HR 0.22, 95% CI 0.05-1.06). In the non-pCR cohort 3-year iDFS was 76.3% versus 69.7% (HR 0.67, 95% CI 0.29-1.54). Multivariable analysis confirmed a durvalumab effect independent of the pCR effect. No new safety signals occurred. - Conclusions - Durvalumab added to NACT in TNBC significantly improved survival despite a modest pCR increase and no adjuvant component of durvalumab. Additional studies are needed to clarify the optimal duration and sequence of checkpoint inhibitors in the treatment of early TNBC. | ||
| 650 | 4 | |a checkpoint inhibitor | |
| 650 | 4 | |a durvalumab | |
| 650 | 4 | |a early triple-negative breast cancer | |
| 650 | 4 | |a neoadjuvant chemotherapy | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Huober, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Braun, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rey, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blohmer, J. -U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Furlanetto, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zahm, D. -M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanusch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomalla, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jackisch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Staib, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Link, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rhiem, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Solbach, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fasching, P. A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nekljudova, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denkert, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Untch, M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 33(2022), 11, Seite 1149-1158 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:11 |g pages:1149-1158 |g extent:10 |a Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2022.07.1940 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753422037917 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230119 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1831514176 |e 4249787982 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete responseAnnals of oncology","physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"11","year":"2022","text":"33(2022), 11, Seite 1149-1158","pages":"1149-1158","volume":"33","extent":"10"},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"language":["eng"],"recId":"320428796","id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"pubHistory":["1.1990 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}]}],"name":{"displayForm":["S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J.-U. Blohmer, J. Furlanetto, D.-M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P.A. Fasching, V. Nekljudova, C. Denkert & M. Untch, on behalf of GBG and AGO-B"]},"id":{"doi":["10.1016/j.annonc.2022.07.1940"],"eki":["1831514176"]},"recId":"1831514176","language":["eng"],"physDesc":[{"extent":"10 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"9 August 2022"}],"title":[{"title_sort":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response"}],"person":[{"display":"Loibl, Sibylle","family":"Loibl","given":"Sibylle","role":"aut"},{"role":"aut","display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss"},{"display":"Huober, J.","family":"Huober","given":"J.","role":"aut"},{"display":"Braun, M.","family":"Braun","given":"M.","role":"aut"},{"family":"Rey","given":"J.","display":"Rey, J.","role":"aut"},{"role":"aut","display":"Blohmer, J. -U.","family":"Blohmer","given":"J. -U."},{"role":"aut","display":"Furlanetto, J.","family":"Furlanetto","given":"J."},{"given":"D. -M.","family":"Zahm","display":"Zahm, D. -M.","role":"aut"},{"family":"Hanusch","given":"C.","display":"Hanusch, C.","role":"aut"},{"display":"Thomalla, J.","family":"Thomalla","given":"J.","role":"aut"},{"given":"C.","family":"Jackisch","display":"Jackisch, C.","role":"aut"},{"family":"Staib","given":"P.","display":"Staib, P.","role":"aut"},{"role":"aut","family":"Link","given":"T.","display":"Link, T."},{"display":"Rhiem, K.","family":"Rhiem","given":"K.","role":"aut"},{"role":"aut","given":"C.","family":"Solbach","display":"Solbach, C."},{"role":"aut","display":"Fasching, P. A.","family":"Fasching","given":"P. A."},{"display":"Nekljudova, V.","family":"Nekljudova","given":"V.","role":"aut"},{"role":"aut","family":"Denkert","given":"C.","display":"Denkert, C."},{"role":"aut","given":"M.","family":"Untch","display":"Untch, M."}],"note":["Gesehen am 19.01.2023"]} | ||
| SRT | |a LOIBLSIBYLNEOADJUVAN9202 | ||